Last reviewed · How we verify
ZILPATEROL
ZILPATEROL is a drug. It is currently FDA-approved.
Zilpaterol works by activating the beta-2 adrenergic receptor, which stimulates muscle protein synthesis and growth.
Zilpaterol is a small molecule modality targeting the beta-2 adrenergic receptor. Its mechanism of action involves activating this receptor, leading to increased muscle protein synthesis and growth. However, its commercial status and approved indications are unknown. Further research is needed to determine its efficacy and safety profile. As a result, it is not currently available for clinical use.
At a glance
| Generic name | ZILPATEROL |
|---|---|
| Target | Beta-2 adrenergic receptor, Mu-type opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Mechanism of action
Think of it like a key that unlocks a door in your muscle cells. When zilpaterol binds to the beta-2 adrenergic receptor, it sends a signal that tells the muscle cells to build more protein, which can help them grow stronger. This process is similar to how your body naturally responds to exercise, but zilpaterol can enhance this effect.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZILPATEROL CI brief — competitive landscape report
- ZILPATEROL updates RSS · CI watch RSS
Frequently asked questions about ZILPATEROL
What is ZILPATEROL?
How does ZILPATEROL work?
What development phase is ZILPATEROL in?
What does ZILPATEROL target?
Related
- Target: All drugs targeting Beta-2 adrenergic receptor, Mu-type opioid receptor
- Therapeutic area: All drugs in Pain